L
ung cancer continues to be the leading cause of cancer death in the United States. 1 Surgical resection is the standard treatment for non-small cell lung cancer that is diagnosed at an early stage without regional or distant metastasis. Optimal surgical therapy in the most favorable subgroup of patients (stage I) produces 5-year disease-specific survival rates of 63%. 2, 3 Non-small cell lung cancer is commonly seen in patients who have extensive smoking histories. Because of this, many patients diagnosed with nonsmall cell lung cancer also have other smokingrelated diseases, such as coronary artery disease, peripheral vascular disease, and COPD. Not infrequently, these diseases or other medical illnesses will render a patient medically inoperable, even though definitive resection might be indicated. The proportion of patients with early-stage lung cancer who are medically inoperable is unknown, but it is estimated to be 15 to 20%. Because the overall incidence of lung cancer is high, many patients find themselves in this unfortunate situation.
Conventional x-ray radiation therapy has been utilized for patients with early-stage but medically inoperable lung cancer. In general, local control and survival rates have been inferior to those produced with surgical resection. 4 -6 Some studies have found that delivering higher doses of radiation therapy may enhance survival. 7, 8 However, because many of these patients have severe underlying pulmonary disease, delivering high doses of thoracic irradiation often is not possible because it will worsen the pulmonary deficiencies that already exist.
Proton beams have a distinct physical advantage over conventional x-ray beams. X-ray beams (photons) can successfully treat malignant tumors if administered in sufficient doses, but in such cases they also deliver substantial doses of irradiation to normal tissues surrounding the tumor. Proton beams produce little side scatter and stop abruptly at any prescribed depth. The pattern of energy deposition is characterized by the Bragg peak, wherein the dose is minimal on entry and reaches a maximum at the stopping region, which is planned to occur in the target volume. 9 Proton beams can be shaped to deliver homogeneous radiation doses to irregular three-dimensional volumes such as those required for lung tumors. These characteristics make it possible to reduce the dose delivered to normal tissue by a factor of one half to one fifth compared with conventional x-ray beams. 10 Accordingly, proton radiation therapy should help minimize the extent and severity of pulmonary injury and so could benefit patients with localized lung cancer and severe underlying pulmonary disease, while simultaneously permitting an increased dose to the primary tumor. At Loma Linda University Medical Center, we use proton-beam radiotherapy to treat early-stage lung cancer patients who are medically inoperable or who refuse surgery; this paper reports our preliminary findings.
Materials and Methods
The Institutional Review Board at Loma Linda University approved a prospective trial that began enrolling patients in July 1994. Eligibility criteria included histologic confirmation of nonsmall cell lung carcinoma (clinical stage I to IIIa) and medical contraindications to surgical resection and/or patient refusal of such treatment. Most patients in this study had significant underlying COPD that precluded definitive surgical resection.
Pretreatment Evaluation
Evaluation prior to study enrollment included a complete history and physical examination, chest radiograph, contrastenhanced thoracic CT, pulmonary function testing, bronchoscopy, and routine blood work. All diagnoses were established with biopsies obtained by means of bronchoscopy or transthoracic needle biopsy. Brain and bone scans and mediastinal node sampling generally were not performed unless there was clinical suspicion of metastasis in these locations. All patients reviewed and signed an Institutional Review Board-approved study-specific consent form prior to enrollment.
Study Design
The study had two treatment arms. Patients were assigned to one of them according to pulmonary reserve and cardiac function (Table 1) . Because mediastinal radiation was judged to be contraindicated in patients who had severely limited pulmonary reserve and/or severe cardiac dysfunction (congestive heart failure), patients in the first arm of the study were given protonbeam radiation therapy that covered only the gross tumor volume as identified on the planning CT scan. No attempt was made to cover areas without radiographic evidence of disease, such as the hilum or mediastinum. These patients received 10 daily fractions of 5.1 cobalt gray equivalents (CGE) 11 for a total of 51 CGE. A typical dose distribution for these patients is shown in Figure 1 .
The second arm of the study included patients judged suitable for mediastinal irradiation. Such patients had a FEV 1 of Ͼ 1 L and no evidence of severe cardiac insufficiency. These patients received photon (x-ray) irradiation that covered the mediastinum, hilum, and primary lung tumor. Mediastinal radiation extended from the sternal notch to 5 cm below the carina with lateral margins of 2 cm. A proton-beam boost was given to the gross tumor volume concurrently with photon irradiation during the last 3 weeks of treatment, as a second daily treatment. The radiation dose given with photons was 45 Gy in 25 fractions; the proton dose was 28.8 CGE in 16 fractions. The total dose to the mediastinum was 45 Gy; the total dose to the gross tumor volume was 73.8 CGE of combined photon and proton irradiation. The spinal cord dose was kept to Ͻ 45 Gy. The entire dose was administered over 5 weeks, with at least a 6-h interval between the two daily fractions during the final 3 weeks.
Technique of Proton Irradiation
Preparation for proton radiation therapy began with construction of a custom-made full-body mold, which was used to ensure reproducible patient immobilization. A CT scan of the chest was then obtained with the patient in the mold (treatment position), and a computerized, three-dimensional treatment plan was developed. From this plan, a wax bolus and lead apertures were fabricated to shape the proton beam both to match the target volume in all three dimensions and to adjust the beam for tissue inhomogeneity. An additional margin was added around the tumor volume to account for tumor motion during normal respiration. Tumor motion was measured for each patient using fluoroscopy under normal respiratory conditions. A dose-volume histogram (DVH) analysis was performed for each patient to quantify the radiation dose received by normal tissues. In general, one to three individual proton-beam portals were used to treat a given patient. Proton treatments typically were delivered through lateral or oblique fields. Figure 1 shows a typical dose distribution achieved with a three-field proton beam arrange- 
Follow-up
After completion of treatment, all patients were followed regularly in the radiation medicine clinic and/or in concert with the patient's primary physician. Follow-up examinations at 1, 3, 6, 9, and 12 months after treatment included chest radiograph, chest CT scan, and pulmonary function testing. After the first year, radiographic imaging was performed twice a year. Routine blood work was also obtained periodically. A radiographic metastatic evaluation was only done if there was clinical suspicion of progressive disease.
Several treatment outcome measures were identified prior to instituting this study. Radiotherapy toxicity was monitored and documented during treatment and at each follow-up visit. Follow-up chest CTs were analyzed for tumor response and pulmonary injury by a panel of physicians including a diagnostic radiologist, radiation oncologist, and pulmonologist. Overall survival and disease-free survival were calculated from the data obtained. In the disease-free survival analysis, if a patient died without clinical or radiographic evidence of disease progression, the event was censored from the analysis at the time of death. Local control was defined as lack of tumor growth within the radiation field. Regional tumor control was defined as disease control within the thorax. Metastatic disease was defined as tumor progression outside of the thorax or the contralateral lung.
Results
Thirty-seven patients were enrolled from July 1994 to January 1998. Two patients had follow-up of Ͻ 3 months and were deemed unevaluable for acute toxicity and tumor response. Thus, 35 evaluable patients were included for analysis with follow-up periods ranging from 3 to 45 months (median, 14 months). The average patient age at enrollment was 72 years. Twenty-seven patients had stage I disease, 2 were in stage II, and 8 patients had stage IIIa tumors. Staging of the mediastinum was done clinically by means of a contrast-enhanced thoracic CT scan; nodes Յ 1 cm in short-axis diameter were considered negative. One patient underwent surgical node sampling prior to treatment. Pretreatment characteristics of all patients are shown in Table 2 . The majority of patients had underlying COPD; the average FEV 1 for all patients was 1.3 L (53% of the predicted value), although the average FEV 1 was 1.1 L (47% predicted) in stage I patients.
All patients were analyzed for the development of acute radiation pneumonitis. Pneumonitis developed in two patients and resolved after a short course of oral steroids. Both of these patients were treated with a combination of photons and proton-beam therapy. None of the patients treated with proton beam only developed clinical pneumonitis. Most patients also participated in a secondary study wherein high-resolution chest CT was used to assess radiographic pulmonary injury. The majority of patients treated with proton beams only showed no demonstrable pulmonary injury on chest CT scan, whereas patients who received a combination of photons and protons did show some areas of increased consolidation. Detailed findings from this study can be found elsewhere. 12 Several patients who received photon irradiation experienced mild esophagitis that neither disrupted therapy nor interfered with the patients' oral intake to a significant degree.
No cardiac or neurologic toxicities were observed. No other significant toxicities were encountered. Actuarial overall survival was calculated utilizing the Kaplan-Meier technique (Table 3) . Actuarial overall survival at 2 years for the entire group was 31%. For the clinical stage I patients, the actuarial 2-year overall survival rate was 39%. The 2-year survival rate for stage IIIa patients was 13%. The disease-free survival rate at 2 years was 63% for the entire group; it was 86% for stage I patients and 19% for stage IIIa patients. Local tumor control at the primary site was 87% at 2 years. Figures 2, 3 show CT images of two selected cases.
Recurrence supervened in nine patients (Table 4) . Three patients developed local tumor recurrence within the radiation field; one patient had simultaneous metastasis to the lung, mediastinal lymph nodes, and brain. Two patients had tumor recurrence within the thorax but outside of the irradiated area. One of these patients developed lymphangitic carcinomatosis; the other developed mediastinal recurrence following proton-beam therapy to the gross tumor volume only.
DVH analysis was performed for all patients. A DVH is generated by the computerized three-dimensional treatment planning system and provides a graphic representation of the proportion of a given structure that has received a given dose of irradiation. Representative DVHs for normal lung tissue in patients from each arm of the study are shown in Figure 4 . Among patients receiving proton-beam therapy only, the 40% isodose line encompassed between 5% and 14% of the total lung volume (median, 8%). In patients receiving photon and proton irradiation, the 40% isodose line encompassed between 19% and 39% of the total lung volume (median, 29%).
Discussion
Standard therapy for early-stage lung cancer patients remains definitive surgical resection. The approximate 2-and 5-year cancer-specific survival rates for pathologically confirmed stage I lung cancer are 81% and 63%, respectively. 2, 3 These numbers dem- onstrate that although surgical resection produces the highest survival rate currently known, many patients do develop recurrences. Adjuvant therapy for this group of patients is currently under investigation. A difficult clinical situation arises when a patient with an early-stage lung tumor is medically unfit for an operation. The most common conditions that render patients medically inoperable are advanced COPD, cardiovascular disease, and poor overall medical condition. Many of these patients are referred for definitive radiotherapy because it is believed that such treatment will cause less severe morbidity and mortality than surgery.
Several reports describe results of treating earlystage lung cancer patients with conventional photon irradiation. In general, survival of patients so treated appears to be inferior to that produced with surgical resection. Published reports of overall and diseasespecific survival for clinical stage I patients at 2 years ranges from 32 to 43% and 31 to 54%, respectively. 4 -8 These studies have reported high local failure rates, ranging from 42 to 55%. Table 5 summarizes recently published results of conventional radiotherapy on early-stage lung cancer.
One disadvantage of using conventional photon radiotherapy for such patients is that their disease is typically staged clinically, in contrast to the more accurate pathologic staging that is obtained in surgical patients. This may explain why there is a higher rate of metastatic failure in patients treated by photon radiation therapy. Even so, it is apparent that local disease control with radiotherapy is in fact inferior to that produced with surgical resection; this may be caused by delivery of inadequate doses to the primary tumor and/or poor targeting techniques. Some studies using conventional photon radiotherapy have demonstrated improved local control and survival with increasing tumor doses. 4, 7, 8 The delivery of doses of radiotherapy capable of eradicating tumors has long been a problem in radiation therapy because of the increased risk of normal tissue damage and complications associated with conventional x-ray beam irradiation of significant volumes of normal tissue surrounding the tumor volume. Certainly, in patients with medically inoperable, localized lung cancer, delivering radiation doses to normal lung tissue is undesirable because of the frequency of underlying emphysema. These patients have minimal reserve to tolerate aggressive thoracic radiotherapy if a significant portion of the lung parenchyma is within the radiation field.
Charged-particle beams such as proton beams have physical properties that allow tumor irradiation with maximal sparing of normal tissue. These properties are superior to what can be accomplished with conventional x-ray beams. [13] [14] [15] Accordingly, we employed proton-beam radiotherapy to deliver highdose tumor irradiation while simultaneously reducing the amount of normal lung irradiation, in the hope of improving local disease control and, possibly, disease-free survival. We also utilized an accelerated treatment schedule that delivered high-dose radiotherapy within a reduced overall treatment time (2 to 5 weeks) compared with a standard fractionated course of treatment (7 to 8 weeks). Protracted fractionation schedules are commonly used in radiation therapy to reduce late toxicity to normal tissue. 16, 17 It has been found, however, that tumor clonogens can proliferate during protracted radiation courses, increasing the likelihood of local tumor regrowth following treatment. 18, 19 A recent randomized trial has demonstrated improved tumor control and survival with use of an accelerated treatment schedule in locally advanced lung cancer. 20 The present study utilized two treatment arms with patients being assigned to one of the arms depending on the presence and/or severity of comorbid conditions such as COPD and cardiac insufficiency. Thus, patients were assigned, not randomized, to a treatment arm, and no direct comparison between the two treatment arms has been made. Although the radiation dose delivered in the treatment arms appear to be different (51 CGE vs 73.8 CGE), the biologically effective dose is similar.
When large daily radiation doses are given as in arm 1 of our study (ie, 5.1 CGE), the biologically equivalent dose is greater then the physical dose actually given. Methods for determining biologically equivalent doses of various fractionation schemes are given elsewhere. 21 Although the radiation doses in the two arms were designed to be similar, the volume of radiated tissue did differ: coverage of the mediastinum and ipsilateral hilum was omitted in patients with severe cardiopulmonary disease because of toxicity concerns. The volume of lung receiving radiation with each technique is shown in Figure 4 , illustrating the essential difference between the two treatment volumes in the two study arms.
Overall survival at 2 years in our study was 31% for the entire group and 39% for clinical stage I patients. These survival rates are low, but most deaths occurred in patients who had no evidence of recurrent cancer. The low survival rates, then, are probably related to the age and poor pulmonary function of our patients. Several reports document poor survival in this group of patients even without a diagnosis of lung cancer [13] [14] [15] [16] ; these studies have shown that the most important prognostic factors for COPD patients are age and FEV 1 . Thus, disease-free survival is likely a more accurate reflection of the efficacy of proton-beam therapy in this group of patients. For the entire group, the disease-free survival rate at 2 years was 63%; for stage I patients, it was 86%. Local control, as assessed by frequent chest CT scans, was 87%. Although these numbers are preliminary, they do appear to compare favorably with results of conventional radiotherapy techniques (Table 5) .
Pulmonary toxicity was also monitored closely in this study. Patients underwent frequent clinical assessment in the radiation oncology and pulmonary clinics. We identified only two cases of clinical pneumonitis, and both resolved following a short course of oral steroids. We also monitored patients for subclinical lung injury radiographically by utilizing high-resolution chest CT scanning. We observed a lesser degree and frequency of pulmonary damage in patients treated in the protons-only arm than in patients receiving the combination of proton and photon irradiation. 12 It is likely that the differences in pulmonary injury we observed in the two groups of patients result from the smaller volume of lung that was irradiated in patients who received protons only, as DVHs suggest (Fig 4) . Overall, the low incidence of significant toxicity suggests that dose escalation is possible, especially in patients treated with local field proton-beam radiotherapy only. Our study suggests that high-dose proton radiotherapy can be administered safely to patients with poor underlying pulmonary function when conformal techniques are used. We believe our study has demonstrated encouraging results in local tumor control and disease-free survival that compare favorably with previously reported data using conventional radiotherapy techniques. Accordingly, we intend to continue to use proton-beam therapy in this group of patients and plan to escalate the proton dose delivered. We also intend to extend this treatment option to patients who have locally advanced lung cancers.
